It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Phosphoinositide 3-kinase (PI3K) signaling in hypothalamic neurons integrates peripheral metabolic cues, including leptin and insulin, to coordinate systemic glucose and energy homeostasis. PI3K is composed of different subunits, each of which has several unique isoforms. However, the role of the PI3K subunits and isoforms in the ventromedial hypothalamus (VMH), a prominent site for the regulation of glucose and energy homeostasis, is unclear. Here we investigated the role of subunit p110β in steroidogenic factor-1 (SF-1) neurons of the VMH in the regulation of metabolism. Our data demonstrate that the deletion of p110β in SF-1 neurons disrupts glucose metabolism, rendering the mice insulin resistant. In addition, the deletion of p110β in SF-1 neurons leads to the whitening of brown adipose tissues and increased susceptibility to diet-induced obesity due to blunted energy expenditure. These results highlight a critical role for p110β in the regulation of glucose and energy homeostasis via VMH neurons.
Metabolism: Enzymatic subunit essential to brain’s glucose responses
A particular subunit of a critical signaling enzyme is needed for neurons inside the brain’s hypothalamus to properly regulate energy metabolism. Ki Woo Kim from Yonsei University College of Dentistry, Seoul, South Korea, and colleagues explored the role that the PI3K enzyme plays in neurons of the ventromedial area toward the front of the hypothalamus, a region involved in regulating hunger and metabolism. Deleting a subunit of PI3K called p110β, which is needed for enzymatic function, made mice less responsive to insulin, the hormone that keeps blood sugar levels at healthy levels. As well as having abnormal glucose metabolism, the mice converted more brown fat, which burns energy, into white fat, which stores energy. They were also more susceptible to diet-induced obesity. The findings point toward p110β as a potential drug target for treating diabetes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Pharmacology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); Long School of Medicine, UT Health San Antonio, Department of Cellular and Integrative Physiology, San Antonio, USA (GRID:grid.267313.2)
2 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Pharmacology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); Yonsei University College of Dentistry, Department of Oral Biology, BK21 PLUS, Seoul, Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
3 Yonsei University College of Dentistry, Department of Oral Biology, BK21 PLUS, Seoul, Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
4 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of São Paulo, Department of Physiology and Biophysics, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
5 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Pharmacology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); Gunma University, Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Maebashi, Japan (GRID:grid.256642.1) (ISNI:0000 0000 9269 4097)
6 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Pharmacology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
7 UT Southwestern Medical Center, Division of Hypothalamic Research, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of Michigan, Department of Molecular and Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)